Innoviva, Inc. (Issuer) has recently filed a Form 4 with the Securities and Exchange Commission (SEC), indicating significant insider activity within the company. Form 4 is a document required to be filed with the SEC whenever there is a material change in the ownership of company securities by insiders. This can include the buying or selling of company stock by directors, officers, or beneficial owners.
Innoviva, Inc. is a pharmaceutical company that focuses on the development and commercialization of innovative medicines for respiratory diseases. With a portfolio of respiratory assets partnered with GlaxoSmithKline, Innoviva aims to provide effective treatment options for patients worldwide. The company’s dedication to advancing respiratory healthcare makes it a key player in the pharmaceutical industry.
For more information on Innoviva, Inc. and its latest developments, you can visit their official website here. Stay tuned for further updates on the company’s progress and future endeavors as detailed in their SEC filings.
Read More:
Innoviva, Inc. (0001080014) (Issuer) Files SEC Form 4: Key Updates Revealed
Leave a Reply